Myeloperoxidase is not associated with scintigraphic myocardial perfusion abnormalities in type 2 diabetic patients with mild stable anginal complaints

Clinica Chimica Acta

Volumn 412, Issue 1-2, 2011, Pages 86-90

  Wiersma, Jacobijne J ^a   Verberne, Hein J ^a   Meuwese, Marijn C ^a   Stroes, Erik S G ^a   van Miert, Joram N I ^a   van Eck Smit, Berthe L F ^a   Tijssen, Jan G P ^a   Piek, Jan J ^a   Trip, Mieke D ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Diabetes mellitus type 2; Myeloperoxidase; Myocardial ischemia; Myocardial perfusion scintigraphy

Indexed keywords

C REACTIVE PROTEIN; CYSTATIN C; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MYELOPEROXIDASE; TETROFOSMIN TC 99M; THALLIUM 201;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG USE; ENZYME BLOOD LEVEL; FEMALE; HEART HEMODYNAMICS; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART SCINTISCANNING; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MYOCARDIAL DISEASE; MYOCARDIAL PERFUSION IMAGING; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STABLE ANGINA PECTORIS;

ANGINA PECTORIS; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; ENDOTHELIAL CELLS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; PEROXIDASE; RISK FACTORS;

ANGINA;

EID: 78650514538     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.09.019     Document Type: Article

References (32)

1. Bonow R.O., Gheorghiade M. The diabetes epidemic: a national and global crisis. Am J Med 2004, 116:2-10.
2. Moss S.E., Klein R., Klein B.E. Cause-specific mortality in a population-based study of diabetes. Am J Public Health 1991, 81:1158-1162.
3. Wingard D.L., Barrett-Connor E. Heart disease and diabetes. Diabetes in America 1995, 429-448. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Diabetes Data Group, Bethesda, Md. 2nd ed. M.I. Harris (Ed.).
4. Wackers F.J., Young L.H., Inzucchi S.E., et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diab Care 2004, 27:1954-1961.
5. Klebanoff S.J. Myeloperoxidase: friend and foe. J Leukoc Biol 2005, 77:598-625.
6. Abu-Soud H.M., Hazen S.L. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem 2000, 275:37524-37532.
7. Eiserich J.P., Baldus S., Brennan M.L., et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002, 296:2391-2394.
8. Meuwese M.C., Stroes E.S.G., Hazen S.L., et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk prospective population study. J Am Coll Cardiol 2007, 50:159-165.
9. Brennan M.L., Penn M.S., Van L.F., et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003, 349:1595-1604.
10. Baldus S., Heeschen C., Meinertz T., et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003, 108:1440-1445.
11. Brennan M.L., Hazen S.L. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Curr Opin Lipidol 2003, 14:353-359.
12. Vita J.A., Brennan M.L., Gokce N., et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 2004, 110:1134-1139.
13. Zhang R., Brennan M.L., Fu X., et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001, 286:2136-2142.
14. Wiersma J.J., Meuwese M.C., van Miert J.N., et al. Diabetes mellitus type 2 is associated with higher levels of myeloperoxidase. Med Sci Monit 2008, 14:CR406-CR410.
15. Wiersma J.J., Dijksman L.E., ten Holt W.L., et al. Cardiac complications in type 2 diabetic patients with mild anginal complaints and documented reversible myocardial perfusion defects, results of the MERIDIAN trial. Neth Heart J 2006, 14:409-416.
16. Shao B., Oda M.N., Bergt C., et al. Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I. J Biol Chem 2006, 281:9001-9004.
17. Zhang C., Yang J., Jennings L.K. Leukocyte-derived myeloperoxidase amplifies high-glucose-induced endothelial dysfunction through interaction with high-glucose-stimulated, vascular non-leukocyte-derived reactive oxygen species. Diabetes 2004, 53:2950-2959.
18. Biondi-Zoccai G.G., Abbate A., Liuzzo G., Biasucci L.M. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 2003, 41:1071-1077.
19. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
20. Goraya T.Y., Leibson C.L., Palumbo P.J., et al. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol 2002, 40:946-953.
21. Kumar A.P., Reynolds W.F. Statins downregulate myeloperoxidase gene expression in macrophages. Biochem Biophys Res Commun 2005, 331:442-451.
22. Zhou T., Zhou S.H., Qi S.S., Shen X.Q., Zeng G.F., Zhou H.N. The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome. Clin Chim Acta 2006, 368:168-172.
23. Meuwese M.C., Trip M.D., van W.S., van Miert J.N., Kastelein J.J., Stroes E.S. Myeloperoxidase levels are not associated with carotid atherosclerosis progression in patients with familial hypercholesterolemia. Atherosclerosis 2008, 197:916-921.
24. Nicholls S.J., Hazen S.L. The role of myeloperoxidase in the pathogenesis of coronary artery disease. Jpn J Infect Dis 2004, 57:S21-S22.
25. Naruko T., Ueda M., Haze K., et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002, 106:2894-2900.
26. Rudolph V., Steven D., Gehling U.M., et al. Coronary plaque injury triggers neutrophil activation in patients with coronary artery disease. Free Radic Biol Med 2007, 42:460-465.
27. Exner M., Minar E., Mlekusch W., et al. Myeloperoxidase predicts progression of carotid stenosis in states of low high-density lipoprotein cholesterol. J Am Coll Cardiol 2006, 47:2212-2218.
28. Windhausen F., Hirsch A., Fischer J., et al. Cystatin C for enhancement of risk stratification in non-ST elevation acute coronary syndrome patients with an increased troponin T. Clin Chem 2009, 55:1118-1125.
29. Arcaro G., Cretti A., Balzano S., et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 2002, 105:576-582.
30. Campia U., Sullivan G., Bryant M.B., Waclawiw M.A., Quon M.J., Panza J.A. Insulin impairs endothelium-dependent vasodilation independent of insulin sensitivity or lipid profile. Am J Physiol Heart Circ Physiol 2004, 286:H76-H82.
31. Delgado A. Hyperinsulinemia and not glucose level is a predisposing factor to endothelial dysfunction. Am J Cardiol 2006, 97:590.
32. Baldus S., Rudolph V., Roiss M., et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation 2006, 113:1871-1878.